Efficacy and Safety of Remimazolam (CNS7056) Compared to Propofol for Intravenous Anesthesia During Elective Surgery

NCT03661489 | Completed Phase 3 DMC

• 1 other identifier: CNS7056-022
• Study Type: interventional
• Target: 469
• Locations: 1 country
• Sites: 1

Brief Summary

A phase III confirmatory trial evaluating the efficacy and safety of remimazolam (CNS7056) compared to propofol for intravenous anesthesia during elective surgery in ASA Class III/IV patients.

Conditions

Anesthesia, Intravenous

Keywords

remimazolam

Outcome Measures

Primary Outcomes (1)

• Percentage (%) of time of Narcotrend Index (NCI) values ≤ 60 during maintenance phase of general anesthesia (defined as time between the first skin incision and the completion of the last skin suture)

  The primary efficacy endpoint (PEP) is the anesthetic effect of remimazolam and propofol assessed as percent (%) of time of NCI ≤60 during the maintenance phase of general anesthesia

  maintenance phase of general anesthesia (time between the first skin incision and the completion of the last skin suture)

Secondary Outcomes (1)

• Number of events of critical decrease(s) in mean arterial blood pressure (MAP)

  From start of Investigational Medicinal Product (IMP) administration until 15 minutes after first skin incision

Other Outcomes (5)

• Percentage of time of NCI ≤60 and ≥40 during the maintenance phase

  During the maintenance phase of general anesthesia: from first skin incision to last skin suture

• Time from start of IMP administration to loss of consciousness

  During induction of general anesthesia

• Time from stop of IMP to end of extubation

  During recovery phase of general anesthesia

Study Arms (2)

Intravenous Remimazolam 50 mg

EXPERIMENTAL

For induction of general anesthesia, remimazolam is co-administered with remifentanil for analgesia and with a muscle relaxant as necessary. For maintenance of general anesthesia remimazolam is titrated to effect. Administration of boluses of remimazolam is allowed. Remifentanil is continued and/or titrated. Boluses of muscle relaxants are given throughout the surgical procedure as needed.

Drug: Remimazolam

Intravenous Propofol 2%

ACTIVE COMPARATOR

For induction of general anesthesia, propofol is co-administered with remifentanil for analgesia and with a muscle relaxant as necessary. For maintenance of general anesthesia propofol is titrated to effect. Administration of boluses of propofol is allowed. Remifentanil is continued and/or titrated. Boluses of muscle relaxants are given throughout the surgical procedure as needed.

Drug: Propofol

Interventions

Remimazolam DRUG

For induction and maintenance of general anesthesia

Intravenous Remimazolam 50 mg

Propofol DRUG

For induction and maintenance of general anesthesia

Intravenous Propofol 2%

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female ASA III/IV patients at least 18 years old, scheduled for an elective surgical procedure of a minimum duration of approximately 90 minutes under general anesthesia (GA) and planned to be extubated immediately post-operatively.
• Total intravenous GA with the requirement for mechanical ventilation via endotracheal tube and necessary invasive blood pressure (BP) monitoring either due to severity of illness, severity of concomitant diseases, type of surgery or decisions of the anesthesia staff.
• Patients scheduled to stay in the hospital long enough after the surgical procedure to perform all trial follow-up procedures (\~1 day)
• For female patients of childbearing potential: Negative result of a pregnancy test taken shortly before the start of the administration of the IMP as well as consent to use highly effective birth control from the last menstrual cycle prior to the start of the IMP until the end of the trial follow-up procedures. Highly effective methods of birth control include:
• Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation: oral, intravaginal and transdermal
• Progestogen-only hormonal contraception associated with inhibition of ovulation: oral, injectable and implantable
• Intrauterine device (IUD)
• Intrauterine hormone-releasing system (IUS)
• Bilateral tubal occlusion
• Vasectomised partner (provided that the partner is the sole sexual partner of the female patient of childbearing potential and that the vasectomised partner has received medical assessment of the surgical success)
• Sexual abstinence (this method is not acceptable in Switzerland)
• Women who had their last menstruation at least two years ago or who underwent surgical interventions (surgical birth control, bilateral oophorectomy, hysterectomy, etc.) are regarded as having no childbearing potential

You may not qualify if:

• Patients scheduled for spinal anesthesia, epidural anesthesia (central neuraxial anesthesia) or regional anesthesia. The placement of a peridural catheter with a test dose application of a local anesthetic drug (up to 5 mL) to verify correct positioning to achieve post-operative analgesia and the regional administration of local anesthetic for post-operative analgesia after wound closure is accepted.
• Patients undergoing transplant surgery, cardiac surgery, or intracranial neurosurgery, patients which have to be in prone position for surgery, emergency surgery, or any surgical procedure with the need for or scheduled for post-operative ventilator support.
• Patients undergoing surgical procedures that require keeping the BP at a high level, e.g. surgical procedures in beach chair position
• Patients with severe hypertension, i.e., one baseline result of systolic BP 200 mmHg or more and / or diastolic BP of 120 mmHg or more. Baseline is defined as the time after signature of the informed consent form (ICF) and before arrival in the operating room (OR) suite.
• Patients with total bilirubin of ≥3.0 mg/dL or ≥3 times increase in aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) than the institutional reference range in laboratory tests, or any other laboratory results that make the patient unsuitable for the trial. All laboratory tests relevant for subject's enrolment must be performed within 7 days prior to start of IMP\*
• \* If the screening samples for the central laboratory were taken earlier than within the last 7 days prior to start of IMP, the lab parameters relevant for subject's enrolment are to be determined in a local laboratory within 7 days prior to start of IMP. If results from samples taken within 7 days prior to the start of the IMP/the surgery from a local laboratory are available, these can be used. If no results from the last 7 days prior to the start of the IMP/the surgery are available, samples need to be taken for the purpose of this trial and to be analysed in a local laboratory.
• Patients with end stage renal disease (ESRD) requiring scheduled dialysis
• Patients with known anaphylactic reactions to benzodiazepines, propofol, opioid analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), dextran, neuromuscular blocking agents, flumazenil, naloxone, or other anesthetic agents, or a medical condition such that these agents are contraindicated (according to local label)
• Presence of acute alcoholic or illicit drug intoxication, shock or coma state
• Known current dependency from central nervous system depressant drugs or alcohol
• Patients with gastroparesis or delayed gastric emptying, gastric reflux or any other increased risk for gastric aspiration
• Patients with an anticipated (small mouth opening, impaired neck movement, goitre, head and neck tumours or any other anatomical reason) or known airway difficulties or with known difficulties in airway maintenance or mask ventilation
• Patients in whom Narcotrend (NCT) may not provide reliable results due to organic defect of the brain or forehead, or any neurologic disease interfering with the EEG monitoring
• Patients on treatment with valproate
• Any pregnant or breast-feeding patient

Sponsors & Collaborators

• Paion UK Ltd.: lead
• ORION Clinical Services: collaborator
• Simbec Research: collaborator
• Creative Clinical Research GmbH: collaborator

Study Sites (1)

University of Erlangen

Erlangen, Bavaria, 91054, Germany

Location

Related Publications (2)

• Antonik LJ, Goldwater DR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics. Anesth Analg. 2012 Aug;115(2):274-83. doi: 10.1213/ANE.0b013e31823f0c28. Epub 2011 Dec 20.

  PMID: 22190555 BACKGROUND

• Wiltshire HR, Kilpatrick GJ, Tilbrook GS, Borkett KM. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation. Anesth Analg. 2012 Aug;115(2):284-96. doi: 10.1213/ANE.0b013e318241f68a. Epub 2012 Jan 16.

  PMID: 22253270 BACKGROUND

MeSH Terms

Interventions

remimazolam; Propofol

Intervention Hierarchy (Ancestors)

Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals

Study Officials

• Jörg Fechner, Prof. Dr.

  University Erlangen-Nürnberg

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: PARTICIPANT
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 3, 2018
• First Posted: September 7, 2018
• Study Start: July 24, 2018
• Primary Completion: April 2, 2020
• Study Completion: April 2, 2020
• Last Updated: May 28, 2020

Record last verified: 2020-05

Locations

DE (1)